Research programme: antibacterials - NewBiotics

Drug Profile

Research programme: antibacterials - NewBiotics

Alternative Names: Lamectacin; NB 2001; NB 2030; NB 3179; NB 3180; NB 3322; NB-2179

Latest Information Update: 10 Jun 2005

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NewBiotics
  • Class
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bacterial infections; Nosocomial infections

Most Recent Events

  • 10 Jun 2005 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
  • 10 Jun 2005 Discontinued - Preclinical for Nosocomial infections in USA (unspecified route)
  • 26 Jul 2004 NewBiotics has been acquired by Celmed BioSciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top